VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16
November 02 2020 - 7:00AM
VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of first-in-class treatments for cancer, today announced that it
will host a conference call and live audio webcast on Monday,
November 16, 2020 at 8:30am Eastern Time to report third quarter
ended September 30, 2020 financial results and to provide a
corporate update.
Monday,
November 16 @ 8:30amET |
From the US: |
|
877-407-9208 |
International: |
|
201-493-6784 |
Israel: |
|
1 809 406 247 |
Conference ID: |
|
13711944 |
Webcast: |
|
https://edge.media-server.com/mmc/p/5wkkzaat |
About VBLVascular Biogenics Ltd., operating as
VBL Therapeutics, is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
first-in-class treatments for areas of unmet need in cancer and
immune/inflammatory indications. VBL has developed three platform
technologies: a gene-therapy based technology for targeting newly
formed blood vessels with focus on cancer, an antibody-based
technology targeting MOSPD2 for anti-inflammatory and
immuno-oncology applications, and the Lecinoxoids, a family of
small-molecules for immune-related indications. VBL’s lead oncology
product candidate, ofranergene obadenovec (VB-111), is a
first-in-class, targeted anti-cancer gene-therapy agent that is
being developed to treat a wide range of solid tumors. It is
conveniently administered as an IV infusion once every 6-8 weeks.
It has been observed to be well-tolerated in >300 cancer
patients and demonstrated activity signals in a VBL-sponsored “all
comers” Phase 1 trial as well as in three VBL-sponsored
tumor-specific Phase 2 studies. Ofranergene obadenovec is currently
being studied in a VBL-sponsored Phase 3 potential registration
trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024